Biohaven Ltd. Increase (Decrease) in Prepaid Expense and Other Assets
Biohaven Ltd. (BHVN) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$20.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- Biohaven Ltd. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$7.52M, a 265.60% decline year-over-year.
- Biohaven Ltd. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$12.56M, a 273.58% decline year-over-year.
- Biohaven Ltd. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$8.81M.
- Biohaven Ltd. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$6.50M.
- Biohaven Ltd. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$3.53M.
- Biohaven Ltd. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$8.04M.
- Biohaven Ltd. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$27.18M, a 165.74% decline from fiscal 2022.
- Biohaven Ltd. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $41.34M, a 350.19% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$7.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$20.09M 10-Q · filed 2026-08-10 | -$28.90M derived: sum of 3 quarters · filed 2026-08-10 | -$35.40M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$12.56M 10-Q · filed 2026-05-04 | -$21.38M derived: sum of 2 quarters · filed 2026-05-04 | -$27.88M derived: sum of 3 quarters · filed 2026-05-04 | -$23.33M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$8.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$15.31M derived: sum of 2 quarters · filed 2026-03-02 | -$10.77M derived: sum of 3 quarters · filed 2026-08-10 | -$3.53M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | -$6.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.95M derived: sum of 2 quarters · filed 2026-08-10 | $5.28M 10-Q · filed 2025-11-10 | -$3.05M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $4.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $11.78M 10-Q · filed 2026-08-10 | $3.45M derived: sum of 3 quarters · filed 2026-08-10 | -$9.75M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $7.24M 10-Q · filed 2026-05-04 | -$1.09M derived: sum of 2 quarters · filed 2026-05-04 | -$14.30M derived: sum of 3 quarters · filed 2026-05-04 | -$3.43M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | -$8.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$21.53M derived: sum of 2 quarters · filed 2026-03-02 | -$10.66M derived: sum of 3 quarters · filed 2026-03-02 | -$8.04M 10-K · filed 2026-03-02 | ||
| 2024-09-30 | -$13.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.33M derived: sum of 2 quarters · filed 2025-11-10 | $290.00K 10-Q · filed 2025-11-10 | $1.54M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-06-30 | $10.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $13.49M 10-Q · filed 2025-08-11 | $14.74M derived: sum of 3 quarters · filed 2026-03-02 | $25.60M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-03-31 | $2.62M 10-Q · filed 2025-05-12 | $3.87M derived: sum of 2 quarters · filed 2026-03-02 | $14.73M derived: sum of 3 quarters · filed 2026-03-02 | -$24.83M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2023-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $12.11M derived: sum of 2 quarters · filed 2026-03-02 | -$27.45M derived: sum of 3 quarters · filed 2026-03-02 | -$27.18M 10-K · filed 2026-03-02 | ||
| 2023-09-30 | $10.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$28.71M derived: sum of 2 quarters · filed 2024-11-12 | -$28.43M 10-Q · filed 2024-11-12 | -$2.76M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | -$39.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$39.28M 10-Q · filed 2024-08-09 | -$13.61M derived: sum of 3 quarters · filed 2025-03-03 | -$7.32M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-03-31 | $279.00K 10-Q · filed 2024-05-09 | $25.95M derived: sum of 2 quarters · filed 2025-03-03 | $32.24M derived: sum of 3 quarters · filed 2025-03-03 | $44.85M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $25.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $31.96M derived: sum of 2 quarters · filed 2025-03-03 | $44.58M derived: sum of 3 quarters · filed 2025-03-03 | $41.34M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $6.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $18.91M derived: sum of 2 quarters · filed 2023-11-14 | $15.67M 10-Q · filed 2023-11-14 | $11.37M 10-Q · filed 2022-11-09 | $13.96M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $12.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $9.38M 10-Q · filed 2023-07-31 | $7.67M derived: sum of 3 quarters · filed 2024-02-29 | |||
| 2022-03-31 | -$3.24M 10-Q · filed 2023-05-12 | -$4.95M derived: sum of 2 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $9.18M 10-K · filed 2024-02-29 | $9.07M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $10.89M 10-Q · filed 2022-11-09 | |||||
| 2020-12-31 | $2.42M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |